NAV

Nialamide

Identification

Generic Name
Nialamide
DrugBank Accession Number
DB04820
Background

Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 298.3397
Monoisotopic: 298.14297584
Chemical Formula
C16H18N4O2
Synonyms
  • 1-(2-(Benzylcarbamoyl)ethyl)-2-isonicotinoylhydrazine
  • 2-(2-(Benzylcarbamoyl)ethyl)hydrazide isonicotinic acid
  • 2-(2-(Benzylcarbamyl)ethyl)hydrazide isonicotinic acid
  • BEIH
  • Isonicotinic acid 2-((2-benzylcarbamoyl)ethyl)hydrazide
  • Isonicotinic acid, 2-(2-(benzylcarbamoyl)ethyl)hydrazide
  • N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
  • N-benzyl-beta-(isonicotinoylhydrazine)propionamide
  • N-benzyl-beta-(isonicotinylhydrazino)propionamide
  • N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine
  • Nialamida
  • Nialamide
  • Nialamidum
External IDs
  • Lopac-N-1392
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Nialamide was one of the first MAOI (monoamine oxidase inhibitor) antidepressants. It is chemically related to iproniazide, another MAOI derived from isonicotinic acid. //

TargetActionsOrganism
UAmine oxidase [flavin-containing] BNot AvailableHumans
UAmine oxidase [flavin-containing] ANot AvailableHumans
UCatechol O-methyltransferaseNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Nialamide is combined with 1,2-Benzodiazepine.
AbaloparatideNialamide may increase the orthostatic hypotensive activities of Abaloparatide.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Abciximab.
AcarboseNialamide may increase the hypoglycemic activities of Acarbose.
AcebutololNialamide may increase the hypotensive activities of Acebutolol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Delmoneurina / Niamid / Niamide / Nuredal / Surgex

Categories

ATC Codes
N06AF02 — Nialamide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Pyridinecarboxylic acids and derivatives
Alternative Parents
Benzene and substituted derivatives / Heteroaromatic compounds / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid derivative / Carboxylic acid hydrazide / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety
show 9 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
T2Q0RYM725
CAS number
51-12-7
InChI Key
NOIIUHRQUVNIDD-UHFFFAOYSA-N
InChI
InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)
IUPAC Name
N-benzyl-3-[(pyridin-4-yl)formohydrazido]propanamide
SMILES
O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1

References

General References
  1. Benady DR, Clein LJ, Pare CM: Intramuscular nialamide in intractable depression. Dis Nerv Syst. 1965 Dec;26(12):792-4. [Article]
  2. OULES J, CAZABON: [TREATMENT OF DEPRESSIVE STATES WITH INTRAVENOUS NIAMIDE]. Toulouse Med. 1964 Dec;65:1298-302. [Article]
  3. VAISBERG M, McGAHEE CL, RADINGER N, SAUNDERS JC: Nialamide for the treatment of anergy and depression. Dis Nerv Syst. 1959 Aug;20(Suppl):22-5. [Article]
PubChem Compound
4472
PubChem Substance
46506047
ChemSpider
4317
BindingDB
163693
RxNav
7394
ChEBI
94510
ChEMBL
CHEMBL1256841
ZINC
ZINC000001713761
Wikipedia
Nialamide

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)151.6 °CPhysProp
logP0.87HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0873 mg/mLALOGPS
logP0.65ALOGPS
logP0.39Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.65Chemaxon
pKa (Strongest Basic)3.41Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area83.12 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity93.91 m3·mol-1Chemaxon
Polarizability32.07 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9828
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5586
P-glycoprotein substrateNon-substrate0.589
P-glycoprotein inhibitor IInhibitor0.5514
P-glycoprotein inhibitor IINon-inhibitor0.8207
Renal organic cation transporterNon-inhibitor0.6666
CYP450 2C9 substrateNon-substrate0.8668
CYP450 2D6 substrateNon-substrate0.7826
CYP450 3A4 substrateNon-substrate0.6434
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8818
CYP450 2D6 inhibitorInhibitor0.816
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7334
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7368
BiodegradationNot ready biodegradable0.9791
Rat acute toxicity2.2756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7944
hERG inhibition (predictor II)Inhibitor0.5599
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.64 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-056u-9500000000-09562bed5beb21b860eb
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0002-0981000000-1b525a17732679e11621
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0fk9-4900000000-edf91905d0d264f001ea
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0981000000-1b525a17732679e11621
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fk9-4900000000-edf91905d0d264f001ea
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-1910000000-703fad04ae18eb95dd79
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-0920000000-27334fad7f04e70af148
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-007c-9100000000-545ee9214141de39e53c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-1900000000-d30892c1d4ea80352cc4
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-9410000000-0954232e195a23249c68
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4l-8910000000-f60b94ae6576db1c01be
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-185.5656801
predicted
DarkChem Lite v0.1.0
[M-H]-166.83244
predicted
DeepCCS 1.0 (2019)
[M+H]+186.8043801
predicted
DarkChem Lite v0.1.0
[M+H]+169.19044
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.5805801
predicted
DarkChem Lite v0.1.0
[M+Na]+175.28358
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Amine oxidase [flavin-containing] B
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS: Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology. 1989 Aug;28(8):791-7. [Article]
Details2. Amine oxidase [flavin-containing] A
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS: Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology. 1989 Aug;28(8):791-7. [Article]
Details3. Catechol O-methyltransferase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Parvez S, Parvez SH, Youdim MB: Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. Br J Pharmacol. 1975 Feb;53(2):241-6. [Article]

Drug created at September 11, 2007 20:20 / Updated at February 21, 2021 18:51